A total of 65 cases of primary small-bowel tumor were found, and in 33 of these the tumors were malignant. Shallow, Eger and Carty 5 state that primary cancer of the small intestine occurs in 0.1 ...

Other less common conditions leading to intestinal obstruction are strictures due to radiation therapy, mesenteric ischemia and intraluminal tumors such as carcinomas, lymphoma and carcinoid.

About 50% of patients with small intestine neuroendocrine tumors (SI-NETs) have their prognosis negatively impacted by the development of mesenteric fibrosis, but the mechanisms behind these are ...

They're essential in the abdomen, since they provide support and attach the small intestine to the wall of the abdomen. Currently, there's no specific known cause of mesenteric panniculitis.

The colon is part of the large intestine, and it has several different sections: ascending, transverse, descending, and sigmoid. The ascending colon is the first section. It is located in the ...

The mesentery contains lymph nodes — small glands that filter lymphatic fluid — which help remove bacteria and waste products ... resulting in the spread of cancerous tumors outside the intestine.

Adiposity index scores were calculated as the proportion of the mesenteric, retroperitoneal, and epididymal adipose tissues by weight to body mass. Gut permeability and bacterial translocation (BT ...

Mesenteric panniculitis—also known as sclerosing mesenteritis—is a rare and chronic illness. It causes inflammation and scarring of the fatty tissue of your mesentery. Mesentery is a fold of membranes ...

Neuroendocrine tumours (NETs) are rare group of malignancy that originate from neuroendocrine cells present throughout the body. Most patients with NET first present with symptoms associated with ...

The most prevalent small bowel cancers are well-differentiated, low-grade neuroendocrine tumors (NETs). These tumors tend to metastasize despite having slow-growing growth patterns and grades ...

Ascletis Pharma Inc. announces the completion of first patient dosing in the U.S. Phase I clinical trial of ASC61, an oral PD-L1 small molecule inhibitor prodrug, for treatment of advanced solid ...